Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Niigata
Clinical trial register · Japan

Clinical Trials in Niigata, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca15 AbbVie9 Pfizer6 Janssen Research & Development, LLC6 Eli Lilly and Company5
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Niigata

117 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Not yet open
Takeda
Phase 2
36
Nagoya, Kumamoto, Shinjuku-ku, Niigata, Osaka
2026-10-15
Not yet open
Pfizer
Phase 3
600
Sapporo, Akashi, Hidaka, Koto-ku, Niigata
2026-10-09
Not yet open
GlaxoSmithKline
Phase 3
720
Niigata
2026-10-09
Recruiting
AstraZeneca
Phase 2
24
Ginowan-shi, Kagoshima, Kanazawa, Niigata
2026-08-31
Recruiting
Pfizer
Phase 3
336
Kitakyushu-shi, Niigata
2026-07-30
Recruiting
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsASP2138·Folinic acid·Adrucil·Capecitabine
Astellas Pharma Global Development, Inc.
Phase 3
570
Chuo-ku, Niigata
2026-07-28
Recruiting
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-07-08
Recruiting
AbbVie
Phase 3
531
Toyoake, Hirosaki, Fukuoka, Sapporo, Kobe, Sagamihara-shi, Sendai, Niigata
2026-07-02
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
Ipsen
Phase 3
350
Chiba, Hiroshima, Itabashi-ku, Yokohama, Ōmura, Kashihara, Niigata, Suita
2026-05-14
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
356
Fukuoka, Hiroshima, Sapporo, Yokohama, Tokyo, Natori-shi, Niigata, Hirakata
2026-04-28
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
Kobe, Shiwa-gun Yahaba-cho, Koto-ku, Toyoma, Fukuoka, Niigata
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Nagoya, Urayasu, Shinjuku Ku, Kofu, Niigata
2026-03-09
Recruiting
ArriVent BioPharma, Inc.
Phase 3
480
Nagoya, Toyoake, Kashiwa, Kurume-Shi, Sapporo, Akashi-shi, Natori-shi, Niigata
2025-12-17
Recruiting
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed
AstraZeneca
Phase 1/2
152
Bunkyō City, Kashiwa, Kurume-shi, Kyoto, Niigata, Shinjuku-ku, Toyoake-shi
2025-11-24
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
14
Nagoya, Fukuoka, Hiroshima, Sapporo, Kyoto, Sendai, Niigata, Ōsaka-sayama
2025-11-19
Recruiting
Hoffmann-La Roche
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata
2025-10-24
Recruiting
Chugai Pharmaceutical
Phase 1
122
Kashiwa, Tōon, Sakai, Niigata
2025-10-08
Recruiting
Daiichi Sankyo
Phase 3
710
Akashi-shi, Fukuoka, Fukushima, Hidaka-shi, Kōtoku, Kurume-shi, Niigata, Okayama
2025-09-30
Recruiting
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
200
Chiba, Fuchū, Niigata, Sagamihara, Sanda-shi, Sendai
2025-09-30
Recruiting
Pfizer
Phase 3
140
Sendai, Niigata, Osaka, Hamamatsu, Mitaka
2025-09-10
Active, closed
Amgen
Phase 3
350
Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Niigata, Okayama, Hirakata-shi
2025-08-18
Recruiting
AbbVie
Phase 2/3
854
Yokohama, Niigata, Takatsuki, Sunto-gun, Bunkyo-ku, Chuo-Ku
2025-08-03
Active, closed
Pfizer
Phase 3
208
Sendai, Niigata, Hamamatsu, Mitaka, Osaka
2025-07-31
Active, closed
AbbVie
Phase 3
125
Nagoya, Kurume-shi, Kahoku-gun, Ebina-shi, Miyagi-gun, Sendai, Niigata, Osaka
2025-06-19
Active, closed
Stoke Therapeutics, Inc
Phase 3
170
Fukuoka, Hokkaido, Kyoto, Nagoya, Niigata, Okayama, Osaka, Shimotsuke
2025-06-04
Recruiting
Biogen
Phase 3
180
Chia-shi, Urayasu-Shi, Sapporo, Kita-Gun Uchiko-Cho, Sagamihara-Shi Minami-Ku, Yokohama, Miyazaki, Niigata
2025-05-22
By invitation
A Prognostic Study for Patients With Cardiovascular Disease in Niigata
NCT06992284Cardiovascular Diseases, Heart Failure
Niigata University Medical & Dental Hospital
Observational
8,500
Niigata
2025-05-12
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis Bullosa
NCT06917690Epidermolysis Bullosa, Junctional Epidermolysis Bullosa, Epidermolysis Bullosa, Dystrophic, Epidermolysis Bullosa, Junctional
Chiesi Farmaceutici S.p.A.
Phase 3
6
Fukuoka, Kobe, Niigata, Ōta-ku, Sapporo
2025-04-18
Recruiting
Pfizer
Phase 3
674
Kurume, Sendai, Niigata, Hamamatsu, Koto-ku, Mitaka, Shinjuku-ku, Osaka
2025-04-01
Recruiting
Daiichi Sankyo
Phase 3
582
Akashi, Chūōku, Fukushima, Hidaka-Shi, Kōtoku, Kurume-shi, Nagoya, Niigata
2025-03-19
Recruiting
AbbVie
Phase 1/2
252
Nagoya, Hirosaki, Yokohama, Kyoto, Niigata, Takatsuki, Chuo-Ku, Koto-ku
2025-03-06
Active, closed
Amgen
Phase 2
252
Kurume-shi, Sapporo, Yokohama, Niigata, Hirakata-shi, Osaka, Sunto-gun, Koto-ku
2025-02-26
By invitation
Longboard Pharmaceuticals
Phase 3
324
Narita-shi, Okayama, Osaka, Saitama-shi, Mibu-Machi, Kodaira-shi, Niigata, Shizuoka
2025-02-12
Recruiting
Dianthus Therapeutics
Phase 3
256
Niigata, Kawasaki, Tsukuba, Kurashiki, Hirakata, Kawagoe, Ube
2025-02-10
Active, closed
Genmab
Phase 3
584
Nagoya, Kurume, Sapporo, Kawasaki, Sendai, Niigata, Okayama, Hidaka
2025-02-07
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Chūōku, Kashihara-shi, Kōtoku, Kumamoto, Kurume-shi, Niigata, Osakasayama-shi, Sapporo
2025-01-29
Active, closed
H. Lundbeck A/S
Phase 3
401
Nagoya, Toyoake-Shi, Gifu, Sapporo, Sendai, Niigata, Iruma-shi, Bunkyō City
2024-12-03
Active, closed
Kyowa Kirin Co., Ltd.
Phase 3
13
Ōbu, Suita, Waizumi, Fuchū, Yonago, Niigata, Okayama, Osaka
2024-12-01
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
DrugSurovatamig
AstraZeneca
Phase 2
270
Chiba, Kashiwa, Kōtoku, Kumamoto, Niigata, Okayama, Osaka, Yokohama
2024-11-27
Active, closed
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
349
Chiba, Fuchū, Gifu, Niigata, Sagamihara, Sanda-shi, Sendai
2024-10-02
Recruiting
GlaxoSmithKline
Phase 2
393
Chiba, Ehime, Gunma, Hokkaido, Kagawa, Nara, Niigata, Osaka
2024-09-27
Active, closed
Pfizer
Observational
450
Kitakyushu-shi, Kurume-shi, Ebina, Sendai, Niigata, Osaka, Hamamatsu, Bunkyo-ku
2024-08-07
Recruiting
Daiichi Sankyo
Phase 1/2
123
Himeji-shi, Hirakata-shi, Kashiwa, Kōtoku, Kumamoto, Nagaizumi-cho, Niigata, Okayama
2024-07-22
Active, closed
AbbVie
Phase 3
1,400
Nagoya, Toyoake, Obihiro-Shi, Shiwa-gun, Kyoto, Niigata, Ginowan-shi, Osaka
2024-06-27
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
31
Kashiwa-shi, Sendai, Niigata, Osaka, Osakasayama-shi, Sunto-gun, Chuo-ku, Koto-ku
2024-05-07
Recruiting
AstraZeneca
Phase 3
582
Chūōku, Fukuoka, Kashiwa, Kōtoku, Niigata, Osaka, Sakai, Sapporo
2024-04-29
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Funabashi Shi, Hakodate, Hyōgo, Niigata, Okayama, Sakura, Tokyo, Yokohama
2024-04-09
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Yokohama, Sendai, Niigata
2024-02-20
Active, closed
Incyte Corporation
Phase 3
617
Ginowan-shi, Itabashi-ku, Kurume-shi, Kyoto, Niigata, Sapporo, Sendai, Shinjuku-ku
2024-01-30
Active, closed
Janssen Research & Development, LLC
Phase 3
838
Bunkyō City, Fukuoka, Hamamatsu, Kanazawa, Kyoto, Nagasaki, Narita, Niigata
2024-01-22
Recruiting
Yonsei University
Phase 2
198
Kurume, Fukushima, Tsu, Sendai, Niigata, Hidaka, Tokushima, Tokyo
2024-01-22
Active, closed
Merck Sharp & Dohme LLC
Phase 2
19
Nagoya, Sapporo, Yokohama, Sendai, Matsumoto, Niigata, Hidaka, Izumo
2023-10-20
Recruiting
AbbVie
Phase 3
1,500
Kurume-shi, Sagamihara-shi, Niigata, Osaka, Hamamatsu, Mitaka-shi, Shinjuku-ku, Ube-shi
2023-10-11
Recruiting
AbbVie
Phase 3
90
Kobe, Kawasaki-shi, Niigata, Takatsuki-shi, Bunkyo-ku
2023-10-02
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
DrugZipalertinib
Taiho Oncology, Inc.
Phase 2
220
Nagoya, Kashiwa-shi, Fukuoka, Sendai, Niigata, Sayama, Sunto-gun, Chuo Ku
2023-07-31
Active, closed
Niigata University Medical & Dental Hospital
Phase 2
21
Niigata
2023-05-01
Recruiting
Eli Lilly and Company
Phase 3
595
Hamamatsu, Kurume, Mitaka, Miyagi-gun, Niigata, Osaka, Shinjuku-ku, Ube
2023-02-27
Recruiting
Janssen Research & Development, LLC
Phase 2
520
Himeji, Matsusaka, Niigata, Shizuoka, Tokyo, Wakayama
2022-11-11
Active, closed
Gilead Sciences
Phase 3
1,021
Chiba, Ehime, Fukuoka, Hyōgo, Ishikawa, Kanagawa, Miyagi, Niigata
2022-10-12
Active, closed
AstraZeneca
Phase 3
594
Bunkyō City, Chūōku, Kōtoku, Kurashiki-shi, Kurume-shi, Matsuyama, Nagoya, Niigata
2022-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Chūōku, Himeji, Hirakata, Kanagawa, Kurashiki, Kurume, Matsusaka, Niigata
2022-08-05
Recruiting
Toray Industries, Inc
Phase 1/2
49
Nagoya, Fukuoka, Sapporo, Kumamoto, Matsumoto, Niigata, Hidaka, Nagaizumi-chō
2022-07-06
Recruiting
Astellas Pharma Inc
Phase 1
681
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Yokohama, Sendai, Niigata
2022-06-08
Active, closed
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
NCT05064878CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure, Epileptic Spasm, Refractory Seizures
DrugFintepla
Zogenix, Inc.
Phase 3
87
Hiroshima, Niigata, Omura-shi, Shizuoka
2022-03-08
Active, closed
AstraZeneca
Phase 3
390
Chiba, Fukuoka, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata, Osaka
2022-02-21
Active, closed
NewAmsterdam Pharma
Phase 3
9,541
Chiba, Fukuoka, Gunma, Hiroshima, Hyōgo, Ishikawa, Kanagawa, Niigata
2022-02-07
Active, closed
AstraZeneca
Phase 3
1,051
Himeji-shi, Hiroshima, Kashiwa, Kurume-shi, Natori-shi, Niigata, Osaka, Sendai
2022-02-07
Recruiting
ARCAGY/ GINECO GROUP
Phase 2
390
Tokyo, Kashiwanoha, Kurume, Tsukuba, Niigata, Kita-ku, Shimotsuke, Ehime
2022-02-01
Active, closed
Eli Lilly and Company
Phase 3
152
Nagoya, Kashiwa, Himeji, Yokohama, Niigata, Nakatogari, Koto, Yonago
2021-12-20
Active, closed
GlaxoSmithKline
Phase 2
360
Gifu, Hiroshima, Hokkaido, Ishikawa, Kagawa, Kumamoto, Miyagi, Niigata
2021-12-14
Active, closed
Joseph Broderick, MD
Phase 3
860
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Morioka, Niigata
2021-12-03
Active, closed
Janssen Research & Development, LLC
Phase 3
776
Gunma, Hyōgo, Kanagawa, Kobe, Kurume, Nagoya, Niigata, Osaka
2021-11-17
Active, closed
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Active, closed
AbbVie
Phase 1
520
Nagoya, Kashiwa-shi, Yokohama, Kyoto, Niigata, Chuo-ku, Koto-ku, Wakayama
2021-10-13
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Kurume, Suita, Chuo Ku, Minato-Ku, Shinjuku-Ku, Matsuyama, Nagoya, Niigata
2021-10-11
Active, closed
AstraZeneca
Phase 1/2
212
Kashiwa, Niigata, Sendai, Tokyo
2021-09-14
Active, closed
HUYABIO International, LLC.
Phase 3
450
Fukuoka, Matsumoto, Niigata, Okayama, Chuo Ku, Osaka, Nagaizumi-cho, Kōtoku
2021-08-12
Recruiting
Novartis Pharmaceuticals
Phase 3
98
Nagoya, Asahikawa, Sapporo, Takatsuki, Ohtsu, Niigata
2021-07-28
Recruiting
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
NCT04031677Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3
250
Higashiku, Yokohama, Sendai, Chikusa-ku, Shōwaku, Niigata, Kita-ku, Chuo-ku
2021-01-20
Active, closed
AstraZeneca
Phase 3
358
Akashi-shi, Bunkyō City, Chiba, Hiroshima, Kashiwa, Kōtoku, Kyoto, Niigata
2020-12-16
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Fukuoka, Kanazawa, Kashihara, Kawasaki, Niigata, Okayama, Osaka, Saitama
2020-12-11
Active, closed
Amgen
Phase 3
135
Fukuoka, Hokkaido, Hyōgo, Ishikawa, Kyoto, Niigata, Osaka, Tokyo
2020-12-04
Active, closed
Merck Sharp & Dohme LLC
Phase 3
870
Kurume, Kobe, Yokohama, Hirakata, Takatsuki, Fukuoka, Niigata, Osaka
2020-07-06
Recruiting
Chiome Bioscience Inc.
Phase 1
66
Kashiwa, Yokohama, Niigata, Chūō
2020-06-01
Active, closed
Janssen Pharmaceutical K.K.
Phase 2
31
Chūōku, Fukuoka, Hirakata, Matsuyama, Nagoya, Niigata, Sapporo
2020-04-07
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Bunkyō City, Chiba, Fukuoka, Hirosaki, Kawasaki-shi, Kōtoku, Kyoto, Niigata
2020-03-30
Active, closed
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
NCT04082429Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
DrugConcizumab
Novo Nordisk A/S
Phase 3
156
Aichi, Hiroshima, Hyōgo, Niigata, Osaka, Saitama, Shizuoka, Tokyo
2019-11-13
Active, closed
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
NCT04036682Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
DrugZipalertinib
Cullinan Therapeutics Inc.
Phase 1/2
284
Chiba, Niigata, Osaka, Shizuoka, Tokyo
2019-10-31
Recruiting
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
NCT03955445C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
225
Nagoya, Asahikawa, Sapporo, Takatsuki, Ohtsu, Hachiōji, Niigata
2019-10-03
Active, closed
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT03914612Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
DrugsParaplatin·Taxol·Keytruda·Paclitaxel
National Cancer Institute (NCI)
Phase 3
813
Tōon, Kure, Niigata, Saitama
2019-08-22
Active, closed
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
DrugsCis-platinum·CDDP·Tecentriq·Paraplatin
National Cancer Institute (NCI)
Phase 3
544
Sendai, Tōon, Sapporo, Kagoshima, Gunma, Niigata, Mitaka-shi, Hiroshima
2019-07-26
Recruiting
Haihe Biopharma Co., Ltd.
Phase 1/2
183
Ehime, Fukuoka, Kanagawa, Niigata, Osaka, Sapporo, Shizuoka, Tokyo
2019-07-15
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Matsuyama, Nagoya, Niigata, Okayama, Tokushima, Tokyo
2019-07-09
Active, closed
AbbVie
Phase 1
124
Obu-shi, Kobe, Kagoshima, Kawasaki-shi, Sendai, Niigata, Bunkyo-ku
2019-06-24
Active, closed
Regeneron Pharmaceuticals
Phase 3
415
Sapporo, Nagaizumi-Cho, Chuo-ku, Niigata, Osaka
2019-06-04
Recruiting
Eli Lilly and Company
Phase 3
190
Bunkyō, Chiba, Kagoshima, Kanazawa, Niigata, Saitama-shi, Sendai, Shinjuku-ku
2019-04-05
Active, closed
AstraZeneca
Phase 3
724
Akashi-shi, Bunkyō City, Chūōku, Fukuoka, Hirosaki-shi, Hiroshima, Kobe, Niigata
2019-03-06
Recruiting
Distribution of Lymph Node Metastases in Esophageal Carcinoma
NCT03222895Esophageal Neoplasms, Lymph Node Metastases
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Observational
5,000
Niigata, Tokyo
2019-03-01
Active, closed
Hoffmann-La Roche
Phase 3
1,000
Aichi, Ehime, Fukuoka, Hokkaido, Ibaraki, Ishikawa, Miyagi, Niigata
2019-02-28
Active, closed
AstraZeneca
Phase 2
367
Fukuoka, Hiroshima, Kanazawa, Nagoya, Niigata, Sapporo, Sayama, Sunto-gun
2019-01-09
Active, closed
AstraZeneca
Phase 3
216
Hiroshima, Kanazawa, Kashiwa, Nagoya, Niigata, Osaka, Sakaishi, Sapporo
2018-07-19
Active, closed
Hoffmann-La Roche
Phase 3
382
Ehime, Miyagi, Niigata, Numakunai, Okayama, Tokyo, Wakayama
2017-09-20
Recruiting
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
NCT03067181Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor, Malignant Germ Cell Tumor
DrugsBleomycin·Cis-platinum·CDDP·Paraplatin
Children's Oncology Group
Phase 3
1,780
Sendai, Chiba-sgi, Niigata, Higashiku, Sapporo, Kobe, Tsukuba, Yokohama
2017-05-25
Active, closed
Bolton Medical
Not applicable
110
Nagoya, Hiroshima, Sapporo, Kashihara, Niigata, Yufu, Joto-ku, Suita
2017-05-10
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Fukuoka, Kashiwa-shi, Kitaadachi-gun, Kurume-shi, Matsuyama, Nagoya, Niigata, Osaka
2016-09-13
Active, closed
Janssen Research & Development, LLC
Phase 1
751
Chūōku, Hyōgo, Kashiwa, Kurume, Nagoya, Niigata, Osaka, Tokyo
2016-05-24
Active, closed
Hoffmann-La Roche
Phase 2
534
Aichi, Chūō, Hyōgo, Matsuyama, Miyagi, Niigata, Osaka, Shizuoka
2015-11-19
Active, closed
Eli Lilly and Company
Phase 3
493
Nagoya, Chiba, Matsuyama, Sapporo, Nishinomiya, Yokohama, Niigata, Ōsaka-sayama
2014-11-06
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Osakasayama-shi, Sapporo
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Sapporo, Sunto-gun
2013-08-26
Active, closed
NSABP Foundation Inc
Not applicable
1,636
Sendai, Sapporo, Akashi, Morioka, Gunma, Niigata, Matsuyama, Saitama
2013-08
Active, closed
Washington University School of Medicine
Phase 2/3
490
Niigata, Bunkyō City
2012-12
Recruiting
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817Alzheimer's Disease
Washington University School of Medicine
Observational
700
Niigata, Osaka, Tokyo
2009-01
Active, closed
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
DrugsHD204·Bevacizumab-awwb·BP102·Zirabev
National Cancer Institute (NCI)
Phase 3
1,052
Sendai, Kure, Sapporo, Shiwa-gun, Kagoshima, Niigata, Shizuoka, Shinjuku-ku
2007-12-06
Recruiting
Genzyme, a Sanofi Company
Observational
9,000
Kobe, Nankoku, Chiba, Niigata, Osaka, Tokyo
2001-07-31
Rows per page Showing 1–117 of 117
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/niigata

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 117 of those studies with a site in Niigata.

How many clinical trials are recruiting in Niigata?

49 of the 117 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 3 have not yet opened recruitment, 63 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Niigata), 117 studies
PhaseStudiesRecruitingShare
Phase 3692559%
Phase 2211017.9%
Phase 1/21068.5%
Phase 1846.8%
Observational534.3%
Not applicable201.7%
Phase 2/3211.7%

Most active sponsors

Lead sponsors with the most studies (Niigata)
Lead sponsorStudiesRecruiting
AstraZeneca154
AbbVie95
Janssen Research & Development, LLC61
Pfizer63
Eli Lilly and Company53
Amgen40
Hoffmann-La Roche41
Novartis Pharmaceuticals43
Astellas Pharma Global Development, Inc.32
Daiichi Sankyo33
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.